Ambrx Biopharma (Ambrx Biopharma) Change In Receivables : $1.39 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ambrx Biopharma Change In Receivables?

Ambrx Biopharma's change in receivables for the quarter that ended in Jun. 2023 was $0.30 Mil. It means Ambrx Biopharma's Accounts Receivable declined by $0.30 Mil from Dec. 2022 to Jun. 2023 .

Ambrx Biopharma's change in receivables for the fiscal year that ended in Dec. 2022 was $0.86 Mil. It means Ambrx Biopharma's Accounts Receivable declined by $0.86 Mil from Dec. 2021 to Dec. 2022 .

Ambrx Biopharma's Accounts Receivable for the quarter that ended in Jun. 2023 was $0.08 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Ambrx Biopharma's Days Sales Outstanding for the three months ended in Jun. 2023 was 6.44.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ambrx Biopharma's liquidation value for the three months ended in Jun. 2023 was $205.59 Mil.

Ambrx Biopharma Change In Receivables Historical Data

The historical data trend for Ambrx Biopharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ambrx Biopharma Change In Receivables Chart

Ambrx Biopharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Change In Receivables

-0.76

0.42

-0.81

0.86

Ambrx Biopharma Quarterly Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial			-0.32	-0.49	-0.23	1.09	0.30

Ambrx Biopharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.39 Mil.

Ambrx Biopharma (NAS:AMAM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ambrx Biopharma's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.081	/	1.147	*	91
=	6.44

2. In Ben Graham's calculation of liquidation value, Ambrx Biopharma's accounts receivable are only considered to be worth 75% of book value:

Ambrx Biopharma's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	235.089	-	29.564	+	0.75 * 0.081	+	0.5 * 0
=	205.59

Ambrx Biopharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Ambrx Biopharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Ambrx Biopharma (Ambrx Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ambrx Biopharma Inc (NAS:AMAM) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AMAM:USA

Address

10975 North Torrey Pines Road, La Jolla, CA, USA, 92037

Website

https://www.ambrx.com

Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.

Executives

Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Margaret Dalesandro	director	ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Sonja Nelson	officer: Chief Financial Officer	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Daniel J. O'connor	director, officer: President and CEO	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Abhishek Trehan	10 percent owner	WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR
Darwin Global Master Fund, Ltd.	10 percent owner	C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009
Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Janet Loesberg	director	C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kate Hermans	director	C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Xiaowei Chang	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Stephen C. Glover	director	108 DOCKSIDE CIRCLE, WESTON FL 33327
Andrew Aromando	officer: Chief Operating Officer	C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116